The king of life science acquisitions has struck again. Thermo Fisher Scientific has announced plans to acquire Patheon, a Durham, North Carolina-based contract development and manufacturing organization with 9,000 employees worldwide.
Given Lucier's expertise in M&A, it'll be interesting to see how he expands NuVasive's product portfolio beyond this $380 million acquisition.
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
The biggest new healthcare product unveiled at CES this week was undoubtedly Life Technologies Corp.’s (NASDAQ:LIFE) new Ion Proton Sequencer, a bench-top machine that the company says will be able to sequence the entire human genome for $1,000 by the end of the year. (A side note: Illumina Inc. announced the release of a similar […]
Sometimes acquiring other drugmakers is the way to fill your company's development pipeline with new drugs. On Tuesday, Schering-Plough Corp. CEO Fred Hassan, a speaker at the Cleveland Clinic's ongoing Medical Innovation Summit, flew to Texas to launch Saphris, an anti-psychotic drug acquired in 2007.